Incremental value of a gut microbiome score (M-score) for predicting stroke-associated pneumonia beyond the clinical A2DS2 score: A nested case–control study
Acta Microbiologica et Immunologica Hungarica · 2026
DOI: 10.1556/030.2026.02907 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Microbiologica et Immunologica Hungarica, 2026. Verfasst von Yidan Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Emergency Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai City, 519000, Guangdong Province, China. Hauptthemen laut MEDLINE: Stroke, Gastrointestinal Microbiome, Pneumonia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
Stroke-associated pneumonia (SAP) is a major complication of acute ischemic stroke. The brain–gut–lung axis suggests that post-stroke gut dysbiosis may offer independent risk information beyond clinical scores like A 2 DS 2 . The aim of this study was to evaluate the incremental predictive value of early post-stroke gut microbiome biomarkers for SAP and to construct a simplified microbiome risk score (M-score). In a prospective nested case–control study, we identified 63 SAP cases from a cohort of 551 patients with acute ischemic stroke and stool samples were collected 24–72 h post-admission. Cases were matched 1:2 (age, sex) to 126 controls. Gut microbiota was profiled via 16S rRNA sequencing. Three differentially abundant genera (prevalence ≥20%, FDR q < 0.10) were used to construct an M-score via bootstrapped regression. Independent associations were assessed with conditional logistic regression. Incremental value over the A 2 DS 2 score was evaluated using AUC, continuous net reclassification improvement (NRI), and the Brier score. SAP cases exhibited reduced α -diversity and distinct β -diversity (both P < 0.01). Cases had higher Enterococcus and Streptococcus and lower Faecalibacterium levels (all q < 0.05). The M-score was independently associated with SAP (adjusted OR per 1-SD: 1.76, 95% CI: 1.30–2.39, P = 0.001). Adding the M-score to A 2 DS 2 significantly improved prediction: AUC increased from 0.76 to 0.84 (ΔAUC = 0.08, P = 0.009), NRI was 0.31 (95% CI: 0.12–0.51), and the Brier score decreased from 0.18 to 0.16. Results were robust in sensitivity analyses. A gut microbiome score based on three genera provides significant independent and incremental predictive value for SAP over the A 2 DS 2 score, enabling more precise early risk stratification after stroke.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- 1Department of Emergency Medicine, The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai City, 519000, Guangdong Province, China.
- 2Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin City, Heilongjiang Province, China.
- 3Department of Cerebrovascular Diseases, the Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai City, 519000, Guangdong Province, China.
ORCID-Profile: Yidan Zhang, Wenbin Li
Zitieren
APA
Zhang, Y., Dong, Q., & Li, W. (2026). Incremental value of a gut microbiome score (M-score) for predicting stroke-associated pneumonia beyond the clinical A2DS2 score: A nested case–control study. Acta Microbiologica et Immunologica Hungarica. https://doi.org/10.1556/030.2026.02907
Vancouver
Zhang Y, Dong Q, Li W. Incremental value of a gut microbiome score (M-score) for predicting stroke-associated pneumonia beyond the clinical A2DS2 score: A nested case–control study. Acta Microbiologica et Immunologica Hungarica. 2026. doi:10.1556/030.2026.02907
BibTeX
@article{Zhang2026,
author = {Zhang, Yidan and Dong, Qi and Li, Wenbin},
title = {Incremental value of a gut microbiome score (M-score) for predicting stroke-associated pneumonia beyond the clinical A2DS2 score: A nested case–control study},
journal = {Acta Microbiologica et Immunologica Hungarica},
year = {2026},
doi = {10.1556/030.2026.02907}
}
EUVIMED